Atezolizumab,Bevacizumab,Tiragolumab,Tocilizumab,TPST-1120,RO7247669,ADG126
Roche,Adagene,JW Pharma,tempest
['atezo', 'hcc', 'tiragolumab', 'morpheus-liver', 'sky,scraper-1']
 morpheus-liver adding anti-tigit (tiragolumab) to atezo/bev increases orr in unresectable hcc (child-pugh a). now moving into blinded randomized phase 3 called skyscraper-14. #asco23 
GI medical oncologist @DanaFarber | @MayoMN_IMRES | @MUMedicine | Tweets my own. Interests: Translational Onc, GI cancers